M&T Bank Corp Cuts Position in Kenvue Inc. (NYSE:KVUE)

M&T Bank Corp trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 105,547 shares of the company’s stock after selling 1,047 shares during the period. M&T Bank Corp’s holdings in Kenvue were worth $2,254,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KVUE. Graypoint LLC acquired a new position in Kenvue in the third quarter valued at approximately $233,000. Principal Financial Group Inc. boosted its holdings in Kenvue by 3.2% in the third quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company’s stock valued at $54,690,000 after purchasing an additional 73,542 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in Kenvue in the third quarter valued at approximately $307,000. Galvin Gaustad & Stein LLC acquired a new position in Kenvue in the third quarter valued at approximately $214,000. Finally, Verdence Capital Advisors LLC boosted its holdings in Kenvue by 2.5% in the third quarter. Verdence Capital Advisors LLC now owns 40,462 shares of the company’s stock valued at $936,000 after purchasing an additional 989 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. UBS Group decreased their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $23.75.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.46 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a fifty day moving average price of $21.64 and a 200 day moving average price of $22.33. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a market cap of $44.83 billion, a PE ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.